PFM
TSHA icon

Privium Fund Management’s Taysha Gene Therapies TSHA Stock Holding History

Privium Fund Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
198,900
+17,000
+9% +$101K 0.25% 41
2026
Q1 		$813K Buy
181,900
+17,000
+10% +$79K 0.17% 48
2025
Q4 		$907K Buy
164,900
+30,000
+22% +$146K 0.17% 44
2025
Q3 		$441K Hold
134,900
– – 0.08% 52
2025
Q2 		$316K Hold
134,900
– – 0.07% 49
2025
Q1 		$188K Hold
134,900
– – 0.05% 53
2024
Q4 		$233K Buy
134,900
+14,900
+12% +$30.9K 0.05% 56
2024
Q3 		$241K Buy
120,000
+21,500
+22% +$47.2K 0.06% 71
2024
Q2 		$213K Buy
+98,500
New +$287K 0.05% 88

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Privium Fund Management's TSHA Position: Q2 2026 in Review

Privium Fund Management increased its Taysha Gene Therapies (TSHA) stake by 9.3% in Q2 2026, buying an estimated $101K and bringing the position to 198,900 shares worth $1.35M. The position accounts for 0.25% of the portfolio, ranked #41.

Privium Fund Management first reported a position in TSHA in Q2 2024 and has held it in 9 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Privium Fund Management held 198,900 shares of Taysha Gene Therapies worth $1.35M as of Q2 2026.
  • Privium Fund Management bought 17,000 Taysha Gene Therapies shares in Q2 2026, an estimated $101K.
  • Taysha Gene Therapies made up 0.25% of Privium Fund Management's portfolio in Q2 2026, its #41 holding.
  • Privium Fund Management first reported a position in Taysha Gene Therapies in Q2 2024 and has held it in 9 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.